vs
Side-by-side financial comparison of CENTRAL PACIFIC FINANCIAL CORP (CPF) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $72.9M, roughly 1.3× CENTRAL PACIFIC FINANCIAL CORP). CENTRAL PACIFIC FINANCIAL CORP runs the higher net margin — 28.4% vs 25.0%, a 3.4% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 6.0%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.7%).
Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
CPF vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.9M | $92.9M |
| Net Profit | $20.7M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 28.4% | 25.0% |
| Revenue YoY | 6.0% | 23.3% |
| Net Profit YoY | 16.7% | 17.3% |
| EPS (diluted) | $0.78 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $76.3M | $92.9M | ||
| Q3 25 | $74.8M | $67.5M | ||
| Q2 25 | $72.8M | $63.2M | ||
| Q1 25 | $68.8M | $52.6M | ||
| Q4 24 | $58.4M | $75.4M | ||
| Q3 24 | $66.6M | $57.9M | ||
| Q2 24 | $64.0M | $52.7M |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $22.9M | $23.2M | ||
| Q3 25 | $18.6M | $5.1M | ||
| Q2 25 | $18.3M | $-553.0K | ||
| Q1 25 | $17.8M | $-11.2M | ||
| Q4 24 | $11.3M | $19.8M | ||
| Q3 24 | $13.3M | $-901.0K | ||
| Q2 24 | $15.8M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 37.0% | 24.1% | ||
| Q3 25 | 31.6% | 5.1% | ||
| Q2 25 | 32.8% | -3.2% | ||
| Q1 25 | 32.8% | -24.3% | ||
| Q4 24 | 23.0% | 24.5% | ||
| Q3 24 | 25.6% | -4.3% | ||
| Q2 24 | 32.2% | -11.5% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 30.0% | 25.0% | ||
| Q3 25 | 24.8% | 7.5% | ||
| Q2 25 | 25.1% | -0.9% | ||
| Q1 25 | 25.8% | -21.4% | ||
| Q4 24 | 19.4% | 26.3% | ||
| Q3 24 | 20.0% | -1.6% | ||
| Q2 24 | 24.7% | -8.9% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.85 | $0.46 | ||
| Q3 25 | $0.69 | $0.10 | ||
| Q2 25 | $0.67 | $-0.01 | ||
| Q1 25 | $0.65 | $-0.23 | ||
| Q4 24 | $0.42 | $0.40 | ||
| Q3 24 | $0.49 | $-0.02 | ||
| Q2 24 | $0.58 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $76.5M | — |
| Stockholders' EquityBook value | $593.9M | $354.6M |
| Total Assets | $7.5B | $488.0M |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
| Q1 26 | $76.5M | — | ||
| Q4 25 | $76.5M | — | ||
| Q3 25 | $131.5M | — | ||
| Q2 25 | $131.5M | — | ||
| Q1 25 | $131.4M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $156.3M | — | ||
| Q2 24 | $156.2M | — |
| Q1 26 | $593.9M | — | ||
| Q4 25 | $592.6M | $354.6M | ||
| Q3 25 | $588.1M | $321.9M | ||
| Q2 25 | $568.9M | $306.8M | ||
| Q1 25 | $557.4M | $295.5M | ||
| Q4 24 | $538.4M | $292.0M | ||
| Q3 24 | $543.7M | $257.5M | ||
| Q2 24 | $518.6M | $243.0M |
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.4B | $488.0M | ||
| Q3 25 | $7.4B | $453.3M | ||
| Q2 25 | $7.4B | $435.6M | ||
| Q1 25 | $7.4B | $424.6M | ||
| Q4 24 | $7.5B | $432.7M | ||
| Q3 24 | $7.4B | $390.4M | ||
| Q2 24 | $7.4B | $376.8M |
| Q1 26 | 0.13× | — | ||
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | $15.0M | ||
| Q3 25 | $22.2M | $22.1M | ||
| Q2 25 | $34.3M | $8.2M | ||
| Q1 25 | $20.4M | $6.6M | ||
| Q4 24 | $90.5M | $22.2M | ||
| Q3 24 | $21.3M | $10.2M | ||
| Q2 24 | $25.9M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $92.3M | $12.8M | ||
| Q3 25 | $21.4M | $19.5M | ||
| Q2 25 | $32.3M | $81.0K | ||
| Q1 25 | $19.6M | $-7.6M | ||
| Q4 24 | $75.4M | $8.5M | ||
| Q3 24 | $15.6M | $-9.2M | ||
| Q2 24 | $21.3M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 121.0% | 13.8% | ||
| Q3 25 | 28.6% | 28.8% | ||
| Q2 25 | 44.3% | 0.1% | ||
| Q1 25 | 28.4% | -14.5% | ||
| Q4 24 | 129.2% | 11.2% | ||
| Q3 24 | 23.5% | -15.9% | ||
| Q2 24 | 33.2% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 2.4% | ||
| Q3 25 | 1.2% | 3.9% | ||
| Q2 25 | 2.7% | 12.9% | ||
| Q1 25 | 1.3% | 27.0% | ||
| Q4 24 | 25.8% | 18.3% | ||
| Q3 24 | 8.5% | 33.5% | ||
| Q2 24 | 7.3% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.26× | 0.65× | ||
| Q3 25 | 1.20× | 4.35× | ||
| Q2 25 | 1.88× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 7.98× | 1.12× | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CPF
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
